Form 8-K - Current report:
SEC Accession No. 0001493152-25-010035
Filing Date
2025-03-12
Accepted
2025-03-12 16:00:36
Documents
24
Period of Report
2025-03-12
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 43683
2 ex99-1.htm EX-99.1 315587
3 ex99-2.htm EX-99.2 322665
4 ex99-2_001.jpg GRAPHIC 14540
5 ex99-2_002.jpg GRAPHIC 6268
6 ex99-2_003.jpg GRAPHIC 12300
7 ex99-2_004.jpg GRAPHIC 14142
8 ex99-2_005.jpg GRAPHIC 20317
9 ex99-2_006.jpg GRAPHIC 15309
10 ex99-2_007.jpg GRAPHIC 12833
11 ex99-2_008.jpg GRAPHIC 15932
  Complete submission text file 0001493152-25-010035.txt   1142574

Data Files

Seq Description Document Type Size
12 XBRL SCHEMA FILE bctx-20250312.xsd EX-101.SCH 3750
13 XBRL DEFINITION FILE bctx-20250312_def.xml EX-101.DEF 26591
14 XBRL LABEL FILE bctx-20250312_lab.xml EX-101.LAB 36631
15 XBRL PRESENTATION FILE bctx-20250312_pre.xml EX-101.PRE 25215
27 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5708
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-40101 | Film No.: 25731633
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)